Levi & Korsinsky, LLP announces that an HGEN class action lawsuit has been filed on behalf of investors who purchased Humanigen, Inc.(HGEN)securities between May 28, 2021, and July 12, 2022. For more on the HGEN Lawsuit please contact us today.

According to the Humanigen lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) Humanigen’s lead product candidate, lenzilumab, was less effective in treating hospitalized COVID-19 patients than the defendants had represented; (ii) as a result, the U.S. Food and Drug Administration was unlikely to approve the lenzilumab Emergency Use Authorization and the ACTIV-5/BET-B study was unlikely to meet its primary endpoint; (iii) accordingly, lenzilumab’s clinical and commercial prospects were overstated; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

TO LEARN MORE ABOUT THE HGEN CLASS ACTION LAWSUIT, CLICK HERE

If you suffered a loss in Humanigen you have until October 25, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com